Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Angiodynamics Inc
(NQ:
ANGO
)
6.100
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Angiodynamics Inc
< Previous
1
2
Next >
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
October 03, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
September 19, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
September 19, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
September 03, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Participate in Upcoming Investor Conferences
July 29, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
July 16, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024
July 08, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
May 21, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
May 06, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
April 04, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
April 04, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
April 01, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
March 19, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
March 06, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million
February 15, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
January 23, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
January 05, 2024
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
December 21, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024
December 07, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
December 07, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance
October 04, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023
September 12, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation
August 15, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Completes Enrollment for PRESERVE Clinical Study
August 03, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth Conference
July 31, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors
July 24, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance
July 12, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Report Fiscal 2023 Fourth Quarter and Full-Year Financial Results on July 12, 2023
June 20, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Announces Sale of Dialysis Product Portfolio and BioSentry Product to Merit Medical Systems for $100 Million
June 08, 2023
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Present at the Needham Virtual Healthcare Conference
April 11, 2023
From
AngioDynamics, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.